BRAF and colorectal carcinoma: We used two microsatellite-stable (MSS) CRC cell models, RAS/RAF wild-type DiFi and BRAF V600E-mutated WiDr, which are respectively sensitive to the anti-epithelial growth factor receptor (EGFR) antibody cetuximab alone13,21 or in combination with a BRAF inhibitor13, two clinically approved regimens for CRC22–24.